Eli Lilly Shares Ride Higher On Strong Q2 Performance, Diabetes and Weight Loss Treatment Mounjaro Nears $1B Revenue

Benzinga2023-08-08

Eli Lilly And Co (NYSE:LLY) has reported Q2 sales of $$8.31 billion, up 28% Y/Y, beating the consensus of $7.58 billion, due to volume-driven growth from Mounjaro, Verzenio, Jardiance, Taltz.

Excluding revenue from Baqsimi and COVID-19 antibodies in 2022, revenue in Q2 2023 increased 22%.

New Products contributed $1.00 billion to revenue in Q2 2023, led by its diabetes drug Mounjaro, which generated sales of $979.7 million compared to a mere $16 million a year ago.

Diabetes drug Jardiance sales increased 45% to $668.3 million.

Lilly has experienced and continues to expect intermittent delays in fulfilling orders of certain Mounjaro doses, given the significant demand. These delays have impacted and may continue to impact, volume. 

Growth Products revenue increased 16% to $4.93 billion in Q2 2023.

Eli Lilly posted an adjusted EPS of $2.11, beating the consensus of $1.99.

Guidance: The company also raised its annual revenue forecast to $33.4-$33.9 billion from prior guidance of $31.2-$31.7 billion versus the consensus of $31.44 billion.

The company sees adjusted EPS Of $9.70-$9.90 from prior guidance of $8.65-$8.85 compared to the consensus of $8.71.

Earlier on Tuesday, rival Novo Nordisk A/S (NYSE:NVO) said its obesity drug Wegovy (semaglutide) reduced the risk of a major cardiovascular event like a stroke by 20% in overweight or obese people with a history of heart disease in a closely watched SELECT cardiovascular outcomes trial.

Price Action: Shares surged over 17% in morning trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
1